Health Catalyst, Inc. (NASDAQ:HCAT) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $8.00.

Several research analysts recently commented on HCAT shares. Citigroup reduced their price target on Health Catalyst from $7.00 to $6.50 and set a "buy" rating for the company in a research report on Friday, April 25th. Royal Bank of Canada reduced their price target on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating for the company in a research report on Thursday, February 27th. Stifel Nicolaus increased their price target on Health Catalyst from $5.00 to $5.50 and gave the company a "hold" rating in a research report on Thursday, May 8th. Stephens cut their price objective on Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating for the company in a research report on Thursday, March 6th. Finally, KeyCorp decreased their target price on Health Catalyst from $7.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, April 16th.

Insiders Place Their Bets

In other Health Catalyst news, COO Daniel Lesueur sold 16,902 shares of Health Catalyst stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total transaction of $76,397.04. Following the completion of the transaction, the chief operating officer now directly owns 216,250 shares of the company's stock, valued at $977,450. The trade was a 7.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Benjamin Landry sold 13,827 shares of Health Catalyst stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the transaction, the general counsel now directly owns 160,437 shares of the company's stock, valued at approximately $729,988.35. This trade represents a 7.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 41,147 shares of company stock valued at $182,284 over the last ninety days. 2.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Health Catalyst

Hedge funds and other institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN lifted its holdings in shares of Health Catalyst by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 39,355 shares of the company's stock worth $278,000 after buying an additional 8,451 shares in the last quarter. Impax Asset Management Group plc lifted its holdings in shares of Health Catalyst by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock worth $19,442,000 after buying an additional 195,525 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Health Catalyst during the fourth quarter worth $2,044,000. BNP Paribas Financial Markets acquired a new stake in shares of Health Catalyst during the fourth quarter worth $735,000. Finally, Intech Investment Management LLC lifted its holdings in shares of Health Catalyst by 59.7% during the fourth quarter. Intech Investment Management LLC now owns 28,386 shares of the company's stock worth $201,000 after buying an additional 10,611 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company's stock.

Health Catalyst Stock Down 0.3%

NASDAQ HCAT traded down $0.01 during trading hours on Monday, hitting $3.65. 417,746 shares of the company traded hands, compared to its average volume of 598,671. The business's 50-day moving average is $4.07 and its 200-day moving average is $5.67. Health Catalyst has a twelve month low of $3.55 and a twelve month high of $9.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The stock has a market capitalization of $254.04 million, a price-to-earnings ratio of -2.70 and a beta of 1.56.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.